MD Buyline's User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive Quarter Service and support capabilities continue to outperform industry competitors PR Newswire SAINT PAUL, Minn., March 4, 2013 SAINT PAUL, Minn., March 4, 2013 /PRNewswire/ --MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced that its pulmonary function products, service and support continues to outperform industry competitors as well as increasing its margin above Market Average. As published in MD Buyline's User Satisfaction Report^™, MGC Diagnostics has earned the top rating in all categories for its fourth consecutive quarter. Ratings based on user satisfaction ranks MGC Diagnostics system performance, system reliability, installation/implementation, applications training, service response time and service repair quality singularly higher compared to other vendors in this space. (Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO) Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented, "We are pleased to be recognized by our customers in the report from MD Buyline for consistently providing unmatched service and support, relentlessly making improvements and anticipating and solving unmet needs. These core commitments guide our strategy and define our commitment to customers, employees and shareholders making us uniquely qualified to solve today's challenges and uncover solutions for tomorrow's opportunities." About MD Buyline – MD Buyline, the leading provider of healthcare technology and clinical research for reducing the purchasing costs across the healthcare supply chain, provides over 3,000 healthcare providers with unbiased, up-to-the-minute data on vendors, products, services, and user satisfaction ratings to ensure they invest in the right technology and services at the right price. www.mdbuyline.com About MGC Diagnostics MGC Diagnostics Corporation, (formerly Angeion Corporation) through its subsidiary Medical Graphics Corporation, is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com. Cautionary Statement Regarding Forward Looking Statements From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws. These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934. Contact: Gregg O. Lehman, Ph.D. Joe Dorame, Robert Blum, Joe Diaz MGC Diagnostics Corporation Lytham Partners, LLC Chief Executive (602) 889-9700 Officer (651) 484-4874 firstname.lastname@example.org SOURCE MGC Diagnostics Corporation Website: http://www.mgcdiagnostics.com
MD Buyline's User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive
Press spacebar to pause and continue. Press esc to stop.